脑心通胶囊对老年人2型糖尿病颈动脉内膜中层厚度和血浆β血小板球蛋白P选择素及纤溶酶原激活物抑制剂1的影响

The effect of Naoxintong capsule treatment on carotid artery intima-media thickness, serum beta thromboglobulin,P-selectin and plasminogen activator inhibitor-I in elderly type 2 diabetic patients with subclinical atherosclerotic vascular disease

目的探讨脑心通胶囊治疗老年2型糖尿病血管病变患者对其颈动脉内膜中层厚度（IMT）、血浆β-血小板球蛋白（β-TG）、P-选择素（CD62p）和纤溶酶原激活物抑制剂-1（PAI-1）的影响。方法回顾性研究，选择医院2014年6月至2015年5月收治的110例老年2型糖尿病血管病变患者为研究对象。数字抽签随机分为观察组和对照组（各55例），入选患者均给予常规治疗，观察组患者同时给予脑心通胶囊治疗。对比分析两组患者血浆β-TG、CD62p和PAl-1水平变化。结果治疗前，两组患者颈动脉IMT、PAl-1、BTG和CD62p水平比较，差异无统计学意义（均P〉0．05）。治疗后，观察组与对照组患者比较，颈动脉IMT（1．31±0．26）mm比（1．44±0．26）mm，差异有统计学意义（t=4．058，P〈0．05）；观察组患者血浆PAI-1、BTG和CD62P水平与对照组比较，PAI-1（2．23±0．48）μg／L比（2．56±0．61）μg/L、β-TG（29．76±10．24）μg／L比（35．98±10．35）μg／L，CD62P（162．3±21．5）ng／L比（176．96±20．3）ng／L，差异有统计学意义（t值分别为3．965、11．293、14．624，均P〈0．05）。结论脑心通胶囊治疗2型糖尿病亚临床血管病变患者有利于减少颈动脉内膜中层厚度，降低血小板释放活性，减轻患者机体氧化应激反应，从而减轻老年2型糖尿病患者血管病变。

Objective To investigate the effects of Naoxintong Capsule treatment on the carotid artery i ntima-media thickness （ IMT）, plasma beta thromboglobulin （ beta TG）, P selectin （ CD62 p） and plasminogen activator inhibitor-1 （PAI-1）in elderly patients with type 2 diabetes mellitus and subclinical atherosclerotic vascular disease. Methods In retrospective study, 110 cases of elderly patients with type 2 diabetic vascular diseases were selected and admitted as study subjects from June 2014 to May 2015. They were randomized into observation group and control group（n=55,each）. All patients were given routine treatment. The patients in the observation group were treated with Naoxintong Capsule. The levels of plasma β-TG, CD62p and PAl 1 were measured and compared between two groups. Results Before treatment,there were no significant differences in IMT, PAI-1, β- TG and CD62p levels between the two groups（P〉0.05）. After treatment, the observation group versus control group showed an improved four parameters of carotid artery IMT（1.31±0.26）mm vs. （1.44 ±0. 26）mm,PAI-l（2. 23 ±0.48）μg/L vs. （2.56 ±0.61）μg/L,/？TG（29.76 ±10.24）μg/L .vs. （.35.98 ±10.35）μg/L,CD62p（162.3 ± 21.5）ng/L vs. （176.96 ± 20. 3）ng/I.（t=4. 058,3. 965, 11. 293,14. 624 respectively, all P〈0.05） with statistically significant differences. Conclusions Naoxintong Capsule treatment of type 2 diabetic patients with subclinical atherosclerotic vascular disease can reduce carotid intima-media thickness, decrease platelet releasing activity and lower the oxidative stress reaction. Thereby, it protects the vascular endothelium, and alleviates subclinicalatherosclerotic vascular disease in the elderly type 2 diabetic patients.